Comparison of antimicrobial agents as therapy for experimental endocarditis

Texas Heart Institute Journal

Volumn 37, Issue 4, 2010, Pages 400-404

  Sacar, Mustafa ^a   Sacar, Suzan ^a   Cevahir, Nural ^a   Onem, Gokhan ^a   Teke, Zafer ^a   Asan, Ali ^a   Turgut, Huseyin ^a   Adali, Fahri ^a   Kaleli, Ilknur ^a   Susam, Ibrahim ^a   Yaylali, Yalin Tolga ^a   Baltalarli, Ahmet ^a  

^a PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Animal; Anti bacterial agents pharmacology therapeutic use; Disease models; Drug resistance, microbial; Endocarditis, bacterial microbiology drug therapy; Linezolid; Methicillin resistance; Microbial sensitivity tests; Rodents; Staphylococcal infections epidemiology; Staphylococcus aureus drug effects; Teicoplanin; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; LINEZOLID; POLYETHYLENE; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL ENDOCARDITIS; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL INFECTION; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HEART CATHETERIZATION; HEART LEFT VENTRICLE; INOCULATION; LOADING DRUG DOSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; RAT;

ACETAMIDES; ANIMALS; ANTI-INFECTIVE AGENTS; AORTIC VALVE; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; ENDOCARDITIS, BACTERIAL; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; RATS; RATS, WISTAR; TEICOPLANIN; TIME FACTORS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 77957356735     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fowler VG Jr, Scheld WM, Bayer AS. Endocarditis and intravascular infections. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2005. p. 975-1022.
2. Murdoch DR, Corey GR, Hoen B, Miro JM, Fowler VG Jr, Bayer AS, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the InternationalCollaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169(5):463-73.
3. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep 2002;51(26):565-7.
4. Hill EE, Peetermans WE, Vanderschueren S, Claus P, Herregods MC, Herijgers P. Methicillin-resistant versus methicillinsensitive Staphylococcus aureus infective endocarditis. Eur J Clin Microbiol Infect Dis 2008;27(6):445-50.
5. Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential [published erratum appears in Drugs 1991;41(5):716]. Drugs 1990;40(3):449-86.
6. Schindler B. Worldwide spread of resistant Staphylococcus [in German]. Med Monatsschr Pharm 2007;30(4):155-6.
7. Santos Sanches I, Mato R, de Lencastre H, Tomasz A; CEM/ NET Collaborators and the International Collaborators. Patterns of multidrug resistance among methicillin-resistant hospital isolates of coagulase-positive and coagulase-negative staphylococci collected in the international multicenter study RESIST in 1997 and 1998. Microb Drug Resist 2000;6(3): 199-211.
8. Drees M, Boucher H. New agents for Staphylococcus aureus endocarditis. Curr Opin Infect Dis 2006;19(6):544-50.
9. Institute of Laboratory Animal Resources National Research Council: Guide for the care and use of laboratory animals. Washington (DC): National Academy Press; 1996.
10. Kloos WE, Barnerman TL. Staphylococcus and micrococcus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 7th ed. Washington (DC): ASM Press; 1999. p. 264-77.
11. Wikler MA, Low DE, Cockerill FR, Sheehan DJ, Craig WA, Tenover FC, Dudley MN. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2006. p. M7-A7.
12. Barry AL, Craig WA, Nadler H, Reller LB, Sanders CC, Swenson JM. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Wayne (PA): National Committee for Clinical Laboratory Standards; 1997. p. M26-A.
13. Perlman BB, Freedman LR. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J Biol Med 1971;44(2):206-13.
14. Durack DT, Beeson PB. Experimental bacterial endocarditis. I. Colonization of a sterile vegetation. Br J Exp Pathol 1972;53 (1):44-9.
15. Dailey CF, Pagano PJ, Buchanan LV, Paquette JA, Haas JV, Gibson JK. Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 2003;47(8): 2655-8.
16. Entenza JM, Drugeon H, Glauser MP, Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother 1995;39(7):1419-24.
17. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003;47(9):3002-4.
18. Pavie J, Lefort A, Ploy MC, Massias L, Chau F, Garry L, et al. Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis. Antimicrob Agents Chemother 2003;47(6):2018-21.
19. Wilson AP, Gaya H. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother 1996;38(3):507-21.
20. Rubinstein E, Carbon C. Staphylococcal endocarditis-recommendations for therapy. Clin Microbiol Infect 1998;4 Suppl 3:S27-S33.
21. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350(9092):1670-3.
22. Smith TL, Pearson ML, Wilcox KR, Cruz C, Lancaster MV, Robinson-Dunn B, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med 1999;340(7): 493-501.
23. Fekety R. Vancomycin, teicoplanin, and the streptogramins: quinupristin and dalfopristin. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000. p. 382-92.
24. Traber PG, Levine DP. Vancomycin ototoxicity in patient with normal renal function. Ann Intern Med 1981;95(4):458-60.
25. Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev Anti Infect Ther 2004;2(1):51-9.
26. Fass RJ. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Antimicrob Agents Chemother 1991;35(3):553-9.
27. Leclercq R, Nantas L, Soussy CJ, Duval J. Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide- lincosamide-streptogramin antibiotics. J Antimicrob Chemother 1992;30 Suppl A:67-75.
28. Pankey GA, Sabath LD. Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections. Clin Infect Dis 2004;38 (6):864-70.
29. Torres JR, Sanders CV, Lewis AC. Vancomycin concentration in human tissues-preliminary report. J Antimicrob Chemother 1979;5(4):475-7.
30. Nicolau DP, Freeman CD, Nightingale CH, Coe CJ, Quintiliani R. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1994;38(7): 1515-8.
31. Martin C, Bourget P, Alaya M, Sertin A, Atlani C, Ennabli K, Said R. Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues. Antimicrob Agents Chemother 1997;41(5):1150-5.
32. Cremieux AC, Maziere B, Vallois JM, Ottaviani M, Azancot A, Raffoul H, et al. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis 1989;159(5):938-44.
33. Fantin B, Leclercq R, Ottaviani M, Vallois JM, Maziere B, Duval J, et al. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother 1994;38(3):432-7.
34. Jacqueline C, Batard E, Perez L, Boutoille D, Hamel A, Caillon J, et al. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model. Antimicrob Agents Chemother 2002;46(12):3706-11.
35. Bassetti M, Di Biagio A, Del Bono V, Cenderello G, Bassetti D. Successful treatment of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Int J Antimicrob Agents 2004;24(1):83-4.
36. Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005;37(11-12):946-9.
37. Bouanchaud DH. In-vitro and in-vivo synergic activity and fractional inhibitory concentration (FIC) of the components of a semisynthetic streptogramin, RP 59500. J Antimicrob Chemother 1992;30 Suppl A:95-9.
38. Zarrouk V, Bozdogan B, Leclercq R, Garry L, Carbon C, Fantin B. Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 2000;44(5):1168-73.